{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:25:06Z","timestamp":1772252706337,"version":"3.50.1"},"reference-count":56,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Muscular Dystrophy Association Cyprus\/Telethon Cyprus"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In the area of drug research, several computational drug repurposing studies have highlighted candidate repurposed drugs, as well as clinical trial studies that have tested\/are testing drugs in different phases. To the best of our knowledge, the aggregation of the proposed lists of drugs by previous studies has not been extensively exploited towards generating a dynamic reference matrix with enhanced resolution. To fill this knowledge gap, we performed weight-modulated majority voting of the modes of action, initial indications and targeted pathways of the drugs in a well-known repository, namely the Drug Repurposing Hub. Our method, DReAmocracy, exploits this pile of information and creates frequency tables and, finally, a disease suitability score for each drug from the selected library. As a testbed, we applied this method to a group of neurodegenerative diseases (Alzheimer\u2019s, Parkinson\u2019s, Huntington\u2019s disease and Multiple Sclerosis). A super-reference table with drug suitability scores has been created for all four neurodegenerative diseases and can be queried for any drug candidate against them. Top-scored drugs for Alzheimer\u2019s Disease include agomelatine, mirtazapine and vortioxetine; for Parkinson\u2019s Disease, they include apomorphine, pramipexole and lisuride; for Huntington\u2019s, they include chlorpromazine, fluphenazine and perphenazine; and for Multiple Sclerosis, they include zonisamide, disopyramide and priralfimide. Overall, DReAmocracy is a methodology that focuses on leveraging the existing drug-related experimental and\/or computational knowledge rather than a predictive model for drug repurposing, offering a quantified aggregation of existing drug discovery results to (1) reveal trends in selected tracks of drug discovery research with increased resolution that includes modes of action, targeted pathways and initial indications for the investigated drugs and (2) score new candidate drugs for repurposing against a selected disease.<\/jats:p>","DOI":"10.3390\/ijms25105319","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T08:03:08Z","timestamp":1715673788000},"page":"5319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DReAmocracy: A Method to Capitalise on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing"],"prefix":"10.3390","volume":"25","author":[{"given":"Kyriaki","family":"Savva","sequence":"first","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-4077","authenticated-orcid":false,"given":"Margarita","family":"Zachariou","sequence":"additional","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena M.","family":"Bourdakou","sequence":"additional","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-3837","authenticated-orcid":false,"given":"Nikolas","family":"Dietis","sequence":"additional","affiliation":[{"name":"Experimental Pharmacology Laboratory, Medical School, University of Cyprus, Nicosia 2115, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-3363","authenticated-orcid":false,"given":"George M.","family":"Spyrou","sequence":"additional","affiliation":[{"name":"Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.26726","article-title":"Systematic integration of biomedical knowledge prioritizes drugs for repurposing","volume":"6","author":"Himmelstein","year":"2017","journal-title":"Elife"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kropiwnicki, E., Lachmann, A., Clarke, D.J.B., Xie, Z., Jagodnik, K.M., and Ma\u2019ayan, A. (2022). DrugShot: Querying biomedical search terms to retrieve prioritized lists of small molecules. BMC Bioinform., 23.","DOI":"10.1186\/s12859-022-04590-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1177\/1460458220937101","article-title":"Knowledge-driven drug repurposing using a comprehensive drug knowledge graph","volume":"26","author":"Zhu","year":"2020","journal-title":"Health Inform. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1581","DOI":"10.1002\/wcms.1581","article-title":"Application advances of deep learning methods for de novo drug design and molecular dynamics simulation","volume":"12","author":"Bai","year":"2022","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14621","DOI":"10.1073\/pnas.1000138107","article-title":"Discovery of drug mode of action and drug repositioning from transcriptional responses","volume":"107","author":"Iorio","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1073\/pnas.0915125107","article-title":"Repositioning of an existing drug for the neglected tropical disease Onchocerciasis","volume":"107","author":"Gloeckner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/bib\/bbr013","article-title":"Exploiting drug-disease relationships for computational drug repositioning","volume":"12","author":"Dudley","year":"2011","journal-title":"Brief. Bioinform."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100749","DOI":"10.1016\/j.xcrm.2022.100749","article-title":"Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation","volume":"3","author":"Lal","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"eabb8097","DOI":"10.1126\/sciadv.abb8097","article-title":"Structure-based drug designing and immunoinformatics approach for SARS-CoV-2","volume":"6","author":"Panda","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.drudis.2020.03.003","article-title":"Machine learning models for drug\u2013target interactions: Current knowledge and future directions","volume":"25","author":"Prema","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, H., Guo, F., Du, M., Wang, G., and Cao, C. (2022). A novel method for drug-target interaction prediction based on graph transformers model. BMC Bioinform., 23.","DOI":"10.1186\/s12859-022-04812-w"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0b013e3182a35228","article-title":"Antihypertensive drugs decrease risk of Alzheimer disease Ginkgo Evaluation of Memory Study","volume":"81","author":"Yasar","year":"2013","journal-title":"Neurology"},{"key":"ref_16","first-page":"715","article-title":"Antihypertensive Agents and Incident Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis of Observational Studies","volume":"9","author":"Adesuyan","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","article-title":"Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: A meta-analysis of individual participant data from prospective cohort studies","volume":"19","author":"Ding","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2012.690615","article-title":"Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS","volume":"21","author":"Toal","year":"2012","journal-title":"Blood Press"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fncel.2017.00364","article-title":"Striatal G\u03b1olf\/cAMP signal-dependent mechanism to generate levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"11","author":"Goto","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bpsgos.2022.03.010","article-title":"Dysfunction of cAMP\u2013Protein Kinase A\u2013Calcium Signaling Axis in Striatal Medium Spiny Neurons: A Role in Schizophrenia and Huntington\u2019s Disease Neuropathology","volume":"3","author":"Fjodorova","year":"2022","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: A placebo- controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2018","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0168-8278(85)80777-7","article-title":"Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study","volume":"1","author":"Dunk","year":"1985","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eaan6387","DOI":"10.1126\/scisignal.aan6387","article-title":"mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington\u2019s disease","volume":"10","author":"Hamilton","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awt041","article-title":"Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis","volume":"136","author":"Morsali","year":"2013","journal-title":"Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40120-018-0095-y","article-title":"5HT6 Antagonists in the Treatment of Alzheimer\u2019s Dementia: Current Progress","volume":"7","author":"Andrews","year":"2018","journal-title":"Neurol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amjopharm.2012.08.002","article-title":"The effect of HMG-CoA reductase inhibitors on cognition in patients with alzheimer\u2019s dementia: A prospective withdrawal and rechallenge pilot study","volume":"10","author":"Padala","year":"2012","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/jpet.107.120188","article-title":"Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action","volume":"321","author":"Kim","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molbrainres.2004.10.021","article-title":"Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: Role of microglia","volume":"134","author":"Peng","year":"2005","journal-title":"Mol. Brain Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"S\u00e1iz-V\u00e1zquez, O., Gracia-Garc\u00eda, P., Ubillos-Landa, S., Puente-Mart\u00ednez, A., Casado-Yusta, S., Olaya, B., and Santab\u00e1rbara, J. (2021). Depression as a Risk Factor for Alzheimer\u2019 s Disease: A Systematic Review of Longitudinal Meta-Analyses. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091809"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Walczak-Nowicka, \u0141.J., and Herbet, M. (2021). Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179290"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-5-18","article-title":"Tetrabenazine is neuroprotective in Huntington\u2019s disease mice","volume":"5","author":"Wang","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102330","DOI":"10.1016\/j.msard.2020.102330","article-title":"Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone","volume":"44","author":"Foo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4239\/wjd.v5.i6.889","article-title":"Type 2 diabetes mellitus and Alzheimer\u2019s disease","volume":"5","author":"Barbagallo","year":"2014","journal-title":"World J. Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.brainres.2011.08.059","article-title":"AMPK activation inhibits apoptosis and tau hyperphosphorylation mediated by palmitate in SH-SY5Y cells","volume":"1418","author":"Kim","year":"2011","journal-title":"Brain Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-131901","article-title":"Long-term metformin usage and cognitive function among older adults with diabetes","volume":"41","author":"Ng","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnins.2015.00220","article-title":"Noradrenergic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Gannon","year":"2015","journal-title":"Front. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnsys.2011.00031","article-title":"Noradrenaline and Parkinson\u2019s disease","volume":"5","author":"Delaville","year":"2011","journal-title":"Front. Syst. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759091419856811","article-title":"Alterations of Calcium Channels in a Mouse Model of Huntington\u2019 s Disease and Neuroprotection by Blockage of CaV1 Channels","volume":"11","author":"Miranda","year":"2019","journal-title":"ASN Neuro"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-019-0332-6","article-title":"Impaired dopamine metabolism in Parkinson\u2019s disease pathogenesis","volume":"14","author":"Masato","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"14727","DOI":"10.1038\/ncomms14727","article-title":"Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer\u2019s disease","volume":"8","author":"Nobili","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.csbj.2022.03.013","article-title":"Network-based stage-specific drug repurposing for Alzheimer \u2019 s disease","volume":"20","author":"Savva","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100465","DOI":"10.1016\/j.jadr.2023.100465","article-title":"Antidepressants as a potential candidate to reduce microglia activation in neurodegenerative diseases. A systematic review and meta-analysis of preclinical studies","volume":"11","author":"Nicolai","year":"2023","journal-title":"J. Affect. Disord. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fphar.2015.00225","article-title":"The role of serotonin 5-HT2A receptors in memory and cognition","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.27976","article-title":"Hypertension, Antihypertensive Use and the Delayed-Onset of Huntington\u2019s Disease","volume":"35","author":"Steventon","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_46","first-page":"420","article-title":"Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington\u2019s disease","volume":"26","author":"Shekhar","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Barbieri, R., Nizzari, M., Zanardi, I., Pusch, M., and Gavazzo, P. (2023). Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders. Life, 13.","DOI":"10.3390\/life13051191"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Al-Rafiah, A., Magadmi, R., Al-Kaabi, A., and Alsomali, N. (2021). Parkinson\u2019s Disease-Related Biomarkers That May Appear in Amphetamine Abusers. Biomed. Res. Int., 2021.","DOI":"10.1155\/2021\/3081891"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.tiv.2018.10.012","article-title":"Methamphetamine exposure induces neuropathic protein \u03b2-Amyloid expression","volume":"54","author":"Chen","year":"2019","journal-title":"Toxicol. Vitr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tox.2018.07.002","article-title":"Involvement of insulin signalling pathway in methamphetamine-induced hyperphosphorylation of Tau","volume":"408","author":"Xu","year":"2018","journal-title":"Toxicology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of Glutamate and NMDA in Alzheimer\u2019s disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1476-5381.2012.02078.x","article-title":"The atypical antidepressant mianserin exhibits agonist activity at \u03ba-opioid receptors","volume":"167","author":"Olianas","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","first-page":"738","article-title":"Symptomatic AD treatment fails in first phase III","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E320","DOI":"10.1097\/MJT.0000000000000735","article-title":"Clozapine for Treatment-Refractory Behavioral Disturbance in Dementia","volume":"25","author":"Teodorescu","year":"2018","journal-title":"Am. J. Ther."},{"key":"ref_55","unstructured":"Dinesh, M., David, A., and Quraishi, S.N. (2009). Depot pipotiazine palmitate and undecylenate for schizophrenia. Cochrane Database Syst. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"baab017","DOI":"10.1093\/database\/baab017","article-title":"Drugmonizome and Drugmonizome-ML: Integration and abstraction of small molecule attributes for drug enrichment analysis and machine learning","volume":"2021","author":"Kropiwnicki","year":"2021","journal-title":"Database"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:48Z","timestamp":1760107308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25105319"],"URL":"https:\/\/doi.org\/10.3390\/ijms25105319","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.12.523717","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}